BioLineRx (NASDAQ:BLRX) Earns Hold Rating from Analysts at StockNews.com

Equities research analysts at StockNews.com initiated coverage on shares of BioLineRx (NASDAQ:BLRX) in a research report issued on Friday. The firm set a “hold” rating on the biotechnology company’s stock.

Separately, HC Wainwright reiterated a “buy” rating and set a $21.00 target price on shares of BioLineRx in a research note on Wednesday.

BioLineRx Stock Down 1.5 %

BLRX stock opened at $0.44 on Friday. The company has a quick ratio of 1.49, a current ratio of 1.61 and a debt-to-equity ratio of 1.34. The business has a 50 day moving average price of $0.53 and a two-hundred day moving average price of $0.63. The company has a market cap of $35.54 million, a price-to-earnings ratio of -0.99 and a beta of 1.48. BioLineRx has a twelve month low of $0.39 and a twelve month high of $1.93.

BioLineRx (NASDAQ:BLRX) last issued its earnings results on Thursday, August 15th. The biotechnology company reported $0.01 EPS for the quarter, topping the consensus estimate of ($0.08) by $0.09. The business had revenue of $5.39 million for the quarter, compared to the consensus estimate of $3.93 million. Analysts anticipate that BioLineRx will post -0.25 EPS for the current fiscal year.

Institutional Trading of BioLineRx

Hedge funds have recently added to or reduced their stakes in the company. PVG Asset Management Corp acquired a new stake in BioLineRx during the 2nd quarter worth approximately $70,000. Atria Investments Inc lifted its holdings in BioLineRx by 27.9% during the 3rd quarter. Atria Investments Inc now owns 133,974 shares of the biotechnology company’s stock worth $72,000 after purchasing an additional 29,193 shares during the last quarter. Finally, CVI Holdings LLC acquired a new stake in BioLineRx during the 2nd quarter worth approximately $462,000. 1.56% of the stock is owned by institutional investors and hedge funds.

About BioLineRx

BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma.